<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950182</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-002</org_study_id>
    <nct_id>NCT01950182</nct_id>
  </id_info>
  <brief_title>Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer</brief_title>
  <acronym>SYSUCC-002</acronym>
  <official_title>A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare progression-free survival (PFS) of patients
      with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab
      Combined With Chemotherapy or Endocrine Therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-inferiority study to examine Trastuzumab combined with chemotherapy or
      endocrine therapy in patients with metastatic Luminal B2 breast cancer subtype. The main
      purposes of this study are to test the safety and clinical benefit of Trastuzumab combined
      with chemotherapy or endocrine therapy in treating Luminal B2 breast cancer (hormone receptor
      positive and human epidermal growth factor receptor (HER2) positive or amplification). This
      multicentre, randomized study is designed to recruit up to 392 subjects to identify 196
      research subjects for each study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>The interim analysis and the final analysis are expected ot occur 18 and 36 months after the end of recruitment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Palliative chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palliative endocrine therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy combined with trastuzumab</intervention_name>
    <description>Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab</description>
    <arm_group_label>Palliative endocrine therapy</arm_group_label>
    <other_name>Tamoxifen</other_name>
    <other_name>aromatase inhibitors</other_name>
    <other_name>trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy combined with trastuzumab</intervention_name>
    <description>Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab</description>
    <arm_group_label>Palliative chemotherapy</arm_group_label>
    <other_name>Capecitabine</other_name>
    <other_name>Vinorelbine</other_name>
    <other_name>Gemcitabine</other_name>
    <other_name>trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older.

          2. Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.

          3. Histologically confirmed metastatic or local recurrence of breast cancer.

          4. ER positive and/or progesterone receptor (PR) positive, HER-2+ defined as
             immuno-histochemistry3+ staining or FISH+.

          5. Prior adjuvant Trastuzumab therapy is permitted, but disease-free interval (DFI) must
             be more than 12 months.

          6. Patients must have measurable or evaluable disease.

          7. Adequate bone marrow reserve with neutrophils &gt; 1000 and platelets &gt; 100,000.

          8. Adequate renal function with serum creatinine &lt; 2.0.

          9. Adequate hepatic reserve with serum bilirubin &lt; 2.0, alanine transaminase(ALT) &lt; 3
             times the upper limit of normal, and alkaline phosphatase &lt; 5 times the upper limit of
             normal.

         10. Adequate cardiac reserve with at least 45% of Left ventricular ejection fraction
             (LVEF) by echocardiogram.

         11. Able to give informed consent.

         12. Life expectancy of at least 12 weeks.

        Exclusion Criteria:

          1. Pregnant or breast feeding.

          2. ECOG score â‰§2

          3. DFI &lt;12 months.

          4. LVEF &lt; 45% by echocardiogram.

          5. Uncontrolled medical problems.

          6. Evidence of active acute or chronic infection.

          7. Hepatic, renal, or bone marrow dysfunction as detailed above.

          8. Concurrent malignancy or history of other malignancy within the last five years except
             as noted above.

          9. Known severe hypersensitivity to Trastuzumab.

         10. Patients were unable or unwilling to comply with program requirements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong-yu Yuan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhong-yu Yuan, MD</last_name>
    <phone>86-20-87343794</phone>
    <email>yuanzhy@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong-yu Yuan, MD</last_name>
      <phone>86-20-87343794</phone>
      <email>yuanzhygz@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2013</study_first_submitted>
  <study_first_submitted_qc>September 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>January 13, 2018</last_update_submitted>
  <last_update_submitted_qc>January 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>unYat-senU</investigator_title>
  </responsible_party>
  <keyword>Luminal B2 subtype</keyword>
  <keyword>First line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

